Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0BMVBZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Antibody targeted amanitin conjugate
|
|||||
| Synonyms |
Antibody targeted amanitin conjugates (Heidelberg Pharma/Advanced Proteome Therapeutics)
Click to Show/Hide
|
|||||
| Organization |
Heidelberg Pharma AG; Advanced Proteome Therapeutics, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
Alpha-amanitin
|
Payload Info | ||||
| Therapeutic Target |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Site-specific conjugation through the engineered cysteine (THIOMAB).
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.